Stay updated on Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial page.

Latest updates to the Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.5.5 was applied, updating the page from v3.5.4. This is a minor revision that does not change the study details or other substantive content on the page.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4. This indicates a minor metadata version upgrade for the page.SummaryDifference0.1%

- Check44 days agoChange DetectedUpdated the website revision indicator in the page footer from **v3.5.2** to **v3.5.3**.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page revision tag was updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check66 days agoChange DetectedAdded the iRECIST guidelines citation (Lancet Oncology, 2017) to the Publications section and removed the associated erratum notice (Lancet Oncology, 2019).SummaryDifference0.1%

- Check80 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial page.